Imunon GAAP EPS -$6.83 Reported Mar 31, 2026 Imunon reported GAAP EPS of -$6.83 on Mar 31, 2026 (Seeking Alpha). The result raises immediate questions about cash runway and the likelihood of dilutive financing within 6–18 months.

Imunon GAAP EPS -$6.83 Reported Mar 31, 2026: Imunon reported GAAP EPS of -$6.83 on Mar 31, 2026 (Seeking Alpha). The result raises immediate questions about cash runway and the likelihood of dilutive financing… 👈 Read full analysis #Imunon #GAAPEarnings #BiotechNews #SmallCapStocks #CashRunway

A New Era for DNA Vaccines? Imunon’s PlaCCine DNA Platform The global response to the COVID-19 pandemic highlighted the incredible power of nucleic acid vaccines, particularly the rapid development and deployment of mRNA vaccines. However, it also brought to ...

Can DNA vaccines overcome the cold-chain and reactogenicity problems of mRNA? Imunon’s PlaCCine platform just might. Strong T-cell immunity, easy delivery, and protection against Omicron in animal models. go.njmicrobe.org/EXvoFy #DNAVaccine #Imunon #COVID19 #GlobalHealth #NJBiotech